Vorasidenib
Vorasidenib: Pioneering Therapy for Grade 2 Gliomas with IDH Mutations Voranigo is a targeted cancer therapy that inhibits mutated isocitrate dehydrogenase enzymes—specifically IDH1…
Vorasidenib: Pioneering Therapy for Grade 2 Gliomas with IDH Mutations Voranigo is a targeted cancer therapy that inhibits mutated isocitrate dehydrogenase enzymes—specifically IDH1…
First Time FDA Approves Nasal Epinephrine Spray for Anaphylaxis Treatment In a groundbreaking development, ARS Pharmaceuticals has received FDA approval for Neffy, the…